Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. The Company's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, it is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

TypePublic
HQCambridge, US
Founded1989
Size (employees)62 (est)
Websiteiderapharma.com
Idera Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Idera Pharmaceuticals

Sudhir Agrawal

Sudhir Agrawal

Chief Executive Officer and President, Board of Directors
Louis J. Arcudi

Louis J. Arcudi

Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Robert D. Arbeit

Robert D. Arbeit

Vice President, Clinical Development
Timothy M. Sullivan

Timothy M. Sullivan

Vice President, Development Programs and Alliance Management
Show more

Idera Pharmaceuticals Office Locations

Idera Pharmaceuticals has offices in Cambridge and Exton
Cambridge, US (HQ)
167 Sidney Street
Exton, US
505 Eagleview Blvd, Suite 212
Show all (2)
Report incorrect company information

Idera Pharmaceuticals Financials and Metrics

Idera Pharmaceuticals Revenue

Idera Pharmaceuticals's revenue was reported to be $249 k in FY, 2015 which is a 241.1% increase from the previous period.
USD

Net income (Q2, 2018)

(36.1m)

EBIT (Q2, 2018)

(36.6m)

Market capitalization (3-Aug-2018)

2.3m

Closing stock price (3-Aug-2018)

5.5

Cash (30-Jun-2018)

94.0m
Idera Pharmaceuticals's current market capitalization is $2.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

47.0k73.0k249.0k

Revenue growth, %

55%241%

General and administrative expense

16.7m

R&D expense

50.7m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

General and administrative expense

3.8m4.0m3.9m3.8m3.9m4.1m3.9m7.0m12.6m

R&D expense

9.0m7.5m9.3m10.1m9.4m11.5m17.9m13.6m24.4m

Operating expense total

12.8m11.5m13.2m13.9m13.3m15.6m21.8m20.5m37.0m

EBIT

(12.8m)(11.5m)(12.9m)(13.6m)(13.0m)(15.2m)(21.6m)(20.3m)(36.6m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.3m20.0m26.6m80.7m112.6m

Accounts Receivable

Inventories

874.0k1.2m3.1m2.0m

Current Assets

30.3m42.4m63.2m111.0m116.6m
Quarterly
USDQ1, 2018Q2, 2018

Cash

107.5m94.0m

Current Assets

110.1m98.0m

PP&E

1.3m1.2m

Total Assets

111.8m99.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2m)(38.6m)(48.6m)(38.4m)

Depreciation and Amortization

137.0k206.0k488.0k656.0k

Inventories

(676.0k)(329.0k)(1.9m)1.1m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(12.7m)(11.4m)(12.8m)(13.5m)(12.9m)(15.1m)

Accounts Payable

2.8m881.0k958.0k629.0k344.0k1.4m529.0k
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Idera Pharmaceuticals News and Updates

Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors

EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of …

Idera Pharmaceuticals Announces Corporate Organizational Changes

- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors -

Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting  Cash runway into first quarter of 2020

Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split

EXTON, Pa., July 27, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that its Board of Directors has approv…
Report incorrect company information

Idera Pharmaceuticals Blogs

Bryant D. Lim

Bryant D. Lim Michael.Fuccio… Thu, 10/04/2018 - 14:48 Bryant D. Lim Senior Vice President, General Counsel, Secretary of the Board of Directors Mr. Bryant D. Lim joined Idera in September of 2018 as General Counsel and Secretary of the Board of Directors.  Pri…

Howard Pien

Howard Pien Michael.Fuccio… Thu, 10/04/2018 - 14:43 Member of the Compensation Committee Howard Pien Director Mr. Howard Pien was appointed a member of Idera’s Board of Directors in September 2018.  Mr. Pien has worked in the pharmaceutical and biotechnology indus…

Barclays – Gena Wang, Ph.D., CFA

Barclays – Gena Wang, Ph.D., CFA Michael.Fuccio… Thu, 10/04/2018 - 14:35 Gena Wang, Ph.D., CFA Barclays

Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference

Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference Content Import Thu, 08/09/2018 - 07:03 Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference Aug 09, 2018 This release is a backfill from a News Wi…

Idera Pharmaceuticals Company Life and Culture

Report incorrect company information